PTIX Protagenic Therapeutics, Inc. Stock Quote

PTIX [NASD]

Index	-	P/E	-	EPS (ttm)	-0.29	Insider Own	0.90%	Shs Outstand	17.61M	Perf Week	-7.35%
Market Cap	10.60M	Forward P/E	-	EPS next Y	-	Insider Trans	24.32%	Shs Float	13.90M	Perf Month	-2.89%
Income	-4.70M	PEG	-	EPS next Q	-	Inst Own	9.50%	Short Float	0.29%	Perf Quarter	-7.02%
Sales	-	P/S	-	EPS this Y	-24.50%	Inst Trans	0.18%	Short Ratio	1.61	Perf Half Y	-47.63%
Book/sh	0.61	P/B	0.98	EPS next Y	-	ROA	-	Target Price	4.00	Perf Year	-68.80%
Cash/sh	0.50	P/C	1.21	EPS next 5Y	-	ROE	-	52W Range	0.56 - 2.35	Perf YTD	-56.52%
Dividend	-	P/FCF	-	EPS past 5Y	6.50%	ROI	-	52W High	-74.31%	Beta	-
Dividend %	-	Quick Ratio	-	Sales past 5Y	-	Gross Margin	-	52W Low	7.71%	ATR	0.05
Employees	-	Current Ratio	-	Sales Q/Q	-	Oper. Margin	-	RSI (14)	41.83	Volatility	8.43% 8.10%
Optionable	No	Debt/Eq	-	EPS Q/Q	-	Profit Margin	-	Rel Volume	3.55	Prev Close	0.60
Shortable	Yes	LT Debt/Eq	-	Earnings	-	Payout	-	Avg Volume	24.87K	Price	0.60
Recom	2.00	SMA20	-3.00%	SMA50	-13.14%	SMA200	-44.13%	Volume	37,956	Change	0.25%

Apr-26-22 08:15AM	Protagenic Therapeutics to Present at the B. Riley Securities Neuro and Ophthalmology Virtual Investor Conference on April 27th ACCESSWIRE -5.75%
Nov-16-21 09:58AM	Protagenic Therapeutics Announces Third Quarter 2021 Results and Business Update GlobeNewswire
Aug-30-21 09:15AM	Protagenic Therapeutics to Host Virtual Science Review Wednesday, September 8th at 10 AM ET GlobeNewswire
Aug-17-21 07:45AM	Protagenic Therapeutics Announces Second Quarter 2021 Results and Provides Business Update GlobeNewswire
Jul-23-21 04:21PM	Protagenic Therapeutics Updates Timeline for Commencement of Patient Enrollment for PT00114 Clinical Trial GlobeNewswire
Jul-08-21 11:20AM	50+ Companies to Present at the Access to Giving Virtual Investor Conference on July 13th - 15th, 2021 ACCESSWIRE +8.75%
Jul-06-21 06:17AM	Protagenic Therapeutics to Host Webinar with Dr. Maurizio Fava for its Lead Molecule PT00114 on Tuesday, July 13th at 10:00 AM ET GlobeNewswire
Jun-23-21 09:35AM	50+ Companies to Present at the Access to Giving Virtual Investor Conference on July 13th - 15th, 2021 ACCESSWIRE +10.47%
Jun-16-21 09:15AM	Protagenic Therapeutics to Present at the H.C. Wainwright Psychedelics in Psychiatry and Beyond Virtual Conference on June 17th GlobeNewswire
Apr-29-21 03:06PM	Protagenic Therapeutics, Inc. Announces Closing of $13.2 Million Public Offering and Uplisting to Nasdaq GlobeNewswire +5.36%
Apr-26-21 08:58PM	Protagenic Therapeutics, Inc. Announces Nasdaq Uplisting and Pricing of $13.2 Million Public Offering GlobeNewswire -24.29%
Dec-16-20 09:15AM	Dr. Maurizio Fava of Massachusetts General Hospital to Serve as Principal Investigator for PT00114 Clinical Trial GlobeNewswire
Sep-08-20 12:10PM	Protagenic Therapeutics Completes $2.0 Million Convertible Note Financing GlobeNewswire

Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound is PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company is based in New York, New York.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Arrow Alexander K.	Chief Financial Officer	May 18	Buy	0.72	8,000	5,760	151,260	May 18 05:11 PM
Arrow Alexander K.	Chief Financial Officer	May 17	Buy	0.71	23,000	16,330	143,260	May 18 05:11 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience